UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd (URGN) is a biopharmaceutical company that focuses on developing and commercializing treatments for urologic and oncologic diseases. The company's lead product is Jelmyto, which is used to treat low-grade upper tract urothelial cancer, a rare form of bladder cancer that affects the lining of the urinary tract. Jelmyto is a non-surgical treatment that is administered directly into the kidney. UroGen Pharma also has several other product candidates in development, including treatments for bladder cancer and overactive bladder. The company is headquartered in Princeton, New Jersey and was founded in 2004.